中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2017

Multi-slice spiral CT and magnetic resonance imaging features of hepatic focal nodular hyperplasia and their pathological basis

DOI: 10.3969/j.issn.1001-5256.2017.09.019
Research funding:

 

  • Received Date: 2017-04-17
  • Published Date: 2017-09-20
  • Objective To investigate the multi-slice spiral CT ( MSCT) and magnetic resonance imaging ( MRI) features of hepatic focal nodular hyperplasia ( FNH) and their pathological basis, and to improve the accuracy of diagnostic imaging. Methods A retrospective analysis was performed for the MSCT and MRI findings of 40 patients with pathologically confirmed hepatic FNH who were admitted to Wuxi Fourth People's Hospital, Affiliated Hospital of Jiangnan University, from January 2010 to December 2016. Results Of all the 30 patients who underwent MSCT, 24 showed low-density lesions on plain scan, among whom 18 had irregular lower-density shadow ( scar) in the central areas of lesions and 6 had slightly higher density ( fatty liver disease) ; as was shown by the contrast-enhanced scan, all lesions had intense enhancement in the arterial phase with even or uneven density, as well as slightly higher or equal density in the portal venous phase, and 18 patients had delayed enhancement in central low-density lesions or a reduction in the size of such lesions. MRI was performed for 40 patients, and plain scan showed that the lesions were slightly hypointense on T1WI and slightly hyperintense on T2WI and DWI, and 32 patients had star-like, striped, or mottled low signals in lesions. All lesions except scars showed intense enhancement in the arterial phase, slight hyperintensity or isointensity in the portal venous phase, and isointensity in the delayed phase. Of all 40 patients, 32 had hypointensity and delayed enhancement in lesions or a reduction in the size of such lesions, 4 had incomplete ring enhancement around the lesions in the portal venous phase and the delayed phase, and 28 had blood vessels around or inside the lesions. Conclusion MSCT and MRI are specific and accurate in the diagnosis of hepatic FNH, and a combination of these two methods can improve the diagnostic rate of hepatic FNH.

     

  • [1]GIUSEPPE B, MICHAEL P, SANTEE K, et al.Hemodynamic charactization of focal nodular hyperplasia using three-dimensional volume-rendered multidetector CT angiography[J].AJR, 2002, 179 (1) :81-85.
    [2]LUIGI G, GIOVANNI M, MILES A, et al.Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumineenhanceed MR imaging:prospective study[J].Radiology, 2005, 236 (1) :166-168.
    [3]NI CY, ZHANG F, ZHANG CY, et al.The diagnostic value of CTand MRI in the diagnosis of focal nodular hyperplasia[J].J Hepatobiliary Surg, 2015, 23 (4) :262-264. (in Chinese) 倪创业, 张峰, 张传永, 等.CT及MRI在肝脏局灶性结节增生中的诊断价值[J].肝胆外科杂志, 2015, 23 (4) :262-264.
    [4]DICARLO I, URRICO GS, URSINO V, et al.Simultaneous occurrence of adenoma, focal nodular hyperplasia, and hemangioma of the liver:are they derived from a comnlon origin?[J].J Gastrocnterol Hepatol, 2003, 18 (2) :227-230.
    [5]ZHONG ZW, CHEN H, HE JX.CT/MRI Findings and pathologic correlation of hepatic focal nodular hyperplasia[J].Chin J CT and MRI, 2015, 13 (5) :84-86. (in Chinese) 钟志伟, 陈淮, 何建勋.肝脏局灶性结节增生的CT/MRI表现及病理分析[J].中国CT和MRI杂志, 2015, 13 (5) :84-86.
    [6]FUKUKURA Y, NAKASHIMA O, KUSABA A, et al.Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver[J].J Hepatol, 1998, 29 (3) :470-475.
    [7]YANG XW.The value of 64-slice spiral CT in the differential diagnosis of hepatocellular carcinoma and focal nodular hyperplasia[J].Mod J Integr Tradit Chin West Med, 2016, 25 (12) :1344-1345. (in Chinses) 杨秀文.64层螺旋CT对肝癌及肝脏局灶性结节增生的鉴别价值[J].现代中西医结合杂志, 2016, 25 (12) :1344-1345.
    [8]YAN GW, WANG JL, ZHANG C, et al.Advanced study and imaging manifestations of focal nodular hyperplasia of the liver[J/CD].Chin J Clinicians:Electronic Edition, 2015, 9 (5) :829-832. (in Chinese) 严高武, 王金良, 张川, 等.肝脏局灶性结节增生的影像学表现及诊治进展[J/CD].中华临床医师杂志:电子版, 2015, 9 (5) :829-832.
    [9]CHERQUI D.Benign liver tumors[J].J Chir, 2001, 138 (1) :19-26.
  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
  • Cited by

    Periodical cited type(11)

    1. 肖春桃,李贤秋,甘佩灵,潘潇,周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤,牛焕章,杜廷伟,魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅,袁佳,史海涛,戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英,高磊,胡扬喜,胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖,董思思,顾宏图,赵长青,刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉,杨哲,吴力群,邱轩,郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜,陈文显,沈华,王雁,张国雷,慎华平,吴万波,魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立,李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州,向俊峰,周威,唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩,张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.1 %FULLTEXT: 15.1 %META: 80.5 %META: 80.5 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2580) PDF downloads(519) Cited by(23)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return